Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer

References

• American Cancer Society. cited 2020 Dec. https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html
   Google Scholar
• Taiwan Cancer registry. 2019.Cancer registry annual report, 2018 TAIWAN
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. Accessed January 2021
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Armstrong DK. First-line chemotherapy for advanced (stageIII or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer; Vora SR,ed. UpToDate; 2021 Feb 18; cited [2021 Mar 3]. Available from: https://www.uptodate.com/contents/first-line-chemotherapy-for-advanced-stage-iii-or-iv-epithelial-ovarian-fallopian-tubal-and-peritoneal-cancer?source=see_link#H760206841
   Google Scholar
• Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian. Cancer. 2019;37:2317–2328.
   Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936.
   PubMed Web of Science ®Google Scholar
• Wang Q, Peng H, Qi X, et al. Targeted therapies in gynecologica cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther. 2020;5(1):137.
   PubMed Web of Science ®Google Scholar
• Research C for DE and Approved Drugs-Niraparib (ZEJULA). 2018. [cited 2018 Jul 13]. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm548487.htm
   Google Scholar
• Research C for DE and Approved drugs-FDA approves olaparibtablets for maintenance treatment in ovarian cancer. 2018 [cited 2021 Mar 13]. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572143.htm
   Google Scholar
• Research C for DE and. Approved drugs-Rucaparib. 2018 [cited 2021 Mar 13]. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm
   Google Scholar
• National Health insurance Administration. Ministry of health and welfare.national health insurance drug payment items and payment standards; [ cited 2021 Mar 3]. https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC7D09599D25979.
   Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive,recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a doubleblind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8): 852–861.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation. Taiwan. [ cited 2021 Mar 3]. https://www.cde.org.tw/eng/HTA/business
   Google Scholar
• Secord AA, Barnett JC, Ledermann JA, et al. Cost-effectiveness of BRCA1 and BRCA2 mutation testingto target PARP inhibitor use in platinum-sensitiverecurrent ovarian cancer. Int J Gynecol Cancer. 2013;23(5):846–852.
   PubMedGoogle Scholar
• Zhong L, Tran AT, Tomasino T, et al. Cost-effectiveness of niraparib and olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer.J. Manage Care Spec Pharm. 2018;24(12):1219–1228.
   PubMed Web of Science ®Google Scholar
• Cheng LJ, Wrong G, Chay WY, et al. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):441–448.
   Web of Science ®Google Scholar
• Murray CJL, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–251.
   PubMed Web of Science ®Google Scholar
• International Monetary Fund. World economic outlook (April 2019) GDP current price.[ cited 2018 Aug 12]. http://www.imf.org/external/datamapper/NGDPD@WEO/OEMDC/ADVEC/WEOWORLD25
   Google Scholar
• Truven Health Analytics, IBM Watson. Micromedex RED BOOK.database; RED BOOK. 2019. [ cited 2020 Sept 28]. Available from: http://truvenhealth.com/Products/Micromedex/Product-Suites/Clinical-Knowledge/RED-BOOK
   Google Scholar
• Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PloS One. 2018;13(4):e0196007–e0196007.
   PubMed Web of Science ®Google Scholar
• Gray A, Clarke PM, Wolstenholme JL, et al. Applied methods of cost- effectiveness analysis in health care. Oxford, New York.: Oxford University Press; 2010.
   Google Scholar
• Sculpher M. The use of a probabilistic sensitivity analysis for decision making: the example of drug eluting stents. Centre for Health Economics University of York, uk. 2008 Aug 17.
   Google Scholar
• Overview of the beta-PERT distribution for modeling expert data. [ cited 2021 Mar 21]. https://www.riskamp.com/beta-pert
   Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020.J. Natl Cancer Inst. 2011;103(2):117–128.
   Google Scholar
• Smith HJ, Walters Haygood CL, Arend RC, et al. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2015;139(1):59–62.
   PubMed Web of Science ®Google Scholar
• Dottino JA, Moss HA, Lu KH, et al. U.S. food and drug dministration-approved poly (ADP-Ribose) polymerase inhibitor maintenance therapy for recurrent ovarian cancer: a cost-effectiveness analysis. Obstet Gynecol. 2019;133(4):795–802.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–437.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018;19(8):1126–1134.
   PubMed Web of Science ®Google Scholar